<DOC>
	<DOCNO>NCT00277316</DOCNO>
	<brief_summary>This clinical study conduct multiple site determine activity , safety , tolerability XL999 give weekly patient metastatic clear cell renal cell carcinoma ( RCC ) . XL999 small molecule inhibitor multiple kinase include VEGFR , PDGFR , FGFR , FLT-3 , Src , involve tumor cell growth , formation new blood vessel ( angiogenesis ) , metastasis .</brief_summary>
	<brief_title>Study XL999 Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Males female histologically confirm metastatic clear cell RCC Measurable disease accord Response Criteria Solid Tumors ( RECIST ) No prior systemic cytotoxic chemotherapy Subjects receive either prior therapy RCC , systemic immunotherapy ( interleukin2 interferon ) , one agent target VEGF VEGFR ( eg , bevacizumab , sorafenib , sunitinib malate ) may enrol ECOG performance status 0 1 Life expectancy ≥3 month Adequate organ marrow function No malignancy within 5 year Signed informed consent Radiation ≥25 % bone marrow within 30 day XL999 treatment Subjects receive systemic anticancer therapy within 30 day XL999 treatment Subjects recover grade ≤1 within 10 % baseline adverse event due medication administer &gt; 30 day prior study enrollment History know brain metastasis , current spinal cord compression carcinomatous meningitis Uncontrolled and/or intercurrent illness Pregnant breastfeeding female Known HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Kidney cancer</keyword>
	<keyword>Metastatic</keyword>
</DOC>